Analystreport

GlaxoSmithKline plc (NYSE: GSK) had its price target lowered by analysts at Argus to $40.00. They now have a "buy" rating on the stock.

GSK plc American Depositary Shares (Each representing two Ordinary Shares)  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors